Pacira Data Shows Real-World Benefit of Non-Opioid Pain Therapies
Event summary
- Pacira BioSciences presented two real-world studies from its Innovations in Genicular Outcomes Registry (IGOR) at the AAOS 2026 Annual Meeting.
- One study demonstrated EXPAREL® was associated with improved pain, opioid use, function, and length of stay after total knee arthroplasty (TKA).
- The second study showed ioveraº treatment associated with longer-term pain and function improvement (up to 12 months) compared to typical alternatives.
- The EXPAREL study involved 42 patients receiving liposomal bupivacaine versus 183 receiving conventional anesthetics, showing statistically significant pain score reductions.
The big picture
Pacira’s IGOR registry highlights the growing demand for non-opioid pain management solutions, driven by regulatory pressure and patient preference. The registry’s findings provide valuable data to support the clinical effectiveness of Pacira’s therapies, potentially accelerating adoption and expanding market reach. However, the company faces ongoing competition and the need to continually demonstrate the value proposition of its products in a rapidly evolving healthcare landscape.
What we're watching
- Market Adoption
- The pace at which IGOR data influences adoption of EXPAREL and ioveraº within orthopedic practices will determine Pacira’s revenue growth trajectory.
- Regulatory Scrutiny
- Increased reliance on real-world evidence may draw greater scrutiny from the FDA and EMA regarding the long-term efficacy and safety of Pacira’s therapies.
- Competitive Landscape
- How competitors respond to Pacira’s IGOR data and develop alternative non-opioid pain management solutions will shape the long-term market share dynamics.
Related topics